ArticleFrontiers in oncology2026
Recurrent primary intracranial myxofibrosarcoma: a case report and review of the literature.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary intracranial myxofibrosarcoma (MFS) is an exceedingly rare mesenchymal malignancy, with only a few cases reported. We report a 34-year-old male with a right frontal lobe MFS who subsequently developed two non-contiguous recurrences in the right temporal and left frontal lobes. Histopathological examination revealed a stepwise progression from low- to intermediate- to high-grade disease, accompanied by progressively increasing Ki-67 labeling indices. Notably, the pattern of spatially separate recurrences suggests the possibility of cerebrospinal fluid-mediated dissemination. This case highlights the aggressive and heterogeneous nature of intracranial MFS and underscores the importance of long-term, comprehensive follow-up to detect recurrences, particularly at non-contiguous sites.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.